| Title |
Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC
|
|---|---|
| Published in |
Cancer Immunology Research, September 2018
|
| DOI | 10.1158/2326-6066.cir-17-0755 |
| Pubmed ID | |
| Authors |
Fernando C. Santini, Hira Rizvi, Andrew J. Plodkowski, Andy Ni, Mario E. Lacouture, Maya Gambarin-Gelwan, Olivia Wilkins, Elizabeth Panora, Darragh F. Halpenny, Niamh M. Long, Mark G. Kris, Charles M. Rudin, Jamie E. Chaft, Matthew D. Hellmann |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 50% |
| Unknown | 2 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 50% |
| Scientists | 1 | 25% |
| Practitioners (doctors, other healthcare professionals) | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 180 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 180 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 25 | 14% |
| Researcher | 24 | 13% |
| Student > Master | 14 | 8% |
| Student > Bachelor | 13 | 7% |
| Student > Doctoral Student | 11 | 6% |
| Other | 34 | 19% |
| Unknown | 59 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 69 | 38% |
| Biochemistry, Genetics and Molecular Biology | 6 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 3% |
| Nursing and Health Professions | 4 | 2% |
| Neuroscience | 4 | 2% |
| Other | 23 | 13% |
| Unknown | 68 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 20. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 November 2021.
All research outputs
#1,645,106
of 23,136,540 outputs
Outputs from Cancer Immunology Research
#159
of 1,423 outputs
Outputs of similar age
#36,622
of 335,453 outputs
Outputs of similar age from Cancer Immunology Research
#10
of 49 outputs
Altmetric has tracked 23,136,540 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,423 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.1. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 335,453 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 49 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 79% of its contemporaries.